Acute Administration of URB597 Fatty Acid Amide Hydrolase Inhibitor Prevents Attentional Impairments by Distractors in Adolescent Mice.
5-CSRTT
URB597
adolescence
anandamide
attentional control
cognitive functions
endocannabinoid system
fatty acid amide hydrolase
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
03
2019
accepted:
18
06
2019
entrez:
6
8
2019
pubmed:
6
8
2019
medline:
6
8
2019
Statut:
epublish
Résumé
The maturation of attentional control during adolescence might influence later functional outcome or predisposition to psychiatric disorders. During adolescence, the cannabinoid system is particularly sensitive to pharmacological challenges, with potential impact on cognitive functions. Here, we used a recently validated five-choice serial reaction time task protocol to test adolescent C57BL/6J mice. We showed that the pharmacological inhibition (by URB597) of the fatty acid amide hydrolase (FAAH), the major enzyme implicated in anandamide degradation, prevented cognitive disruptions induced by distracting cues in adolescent mice. In particular, these protective effects were indicated by increased accuracy and correct responses and decreased premature responses selectively in the distractor trials. Notably, at the relatively low dose used, we detected no effects in other cognitive, motor, or incentive measures nor long-lasting or rebound effects of FAAH inhibition in cognitive functions. Overall, these data provide initial evidence of selective procognitive effects of FAAH inhibition in measures of attentional control in adolescent mice.
Identifiants
pubmed: 31379568
doi: 10.3389/fphar.2019.00787
pmc: PMC6658611
doi:
Types de publication
Journal Article
Langues
eng
Pagination
787Références
Prostaglandins Other Lipid Mediat. 2000 Apr;61(1-2):3-18
pubmed: 10785538
Neurosci Biobehav Rev. 2000 Jun;24(4):417-63
pubmed: 10817843
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3662-5
pubmed: 11259648
JAMA. 2002 Mar 6;287(9):1123-31
pubmed: 11879109
Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80
pubmed: 12373437
Nat Med. 2003 Jan;9(1):76-81
pubmed: 12461523
Behav Neurosci. 2003 Aug;117(4):695-703
pubmed: 12931955
Nat Rev Neurosci. 2003 Nov;4(11):873-84
pubmed: 14595399
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
Neurobiol Learn Mem. 2004 Mar;81(2):144-9
pubmed: 14990234
J Pharmacol Exp Ther. 2005 Apr;313(1):352-8
pubmed: 15579492
Biol Psychiatry. 2006 Mar 15;59(6):508-15
pubmed: 16199010
Br J Pharmacol. 2006 Feb;147(3):281-8
pubmed: 16331291
J Neurosci. 2006 Feb 1;26(5):1551-61
pubmed: 16452678
Eur Neuropsychopharmacol. 2007 Feb;17(3):180-6
pubmed: 16679004
CNS Drug Rev. 2006 Spring;12(1):21-38
pubmed: 16834756
Neuropsychopharmacology. 2007 May;32(5):1032-41
pubmed: 17047668
Trends Pharmacol Sci. 2007 Feb;28(2):83-92
pubmed: 17222464
Psychopharmacology (Berl). 2007 Jul;193(1):85-96
pubmed: 17387457
Science. 2007 May 25;316(5828):1212-6
pubmed: 17525344
Eur J Pharmacol. 2008 May 13;585(2-3):458-63
pubmed: 18423599
Learn Mem. 2008 Apr 25;15(5):368-72
pubmed: 18441294
Addict Biol. 2008 Jun;13(2):253-63
pubmed: 18482434
Brain Res. 2009 Feb 27;1257:25-31
pubmed: 19133243
Learn Mem. 2009 Apr 29;16(5):332-7
pubmed: 19403796
Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):371-82
pubmed: 19588184
J Neurosci. 2010 Jun 2;30(22):7664-71
pubmed: 20519541
Biol Psychiatry. 2011 Sep 1;70(5):479-86
pubmed: 21684528
Neuropharmacology. 2011 Oct-Nov;61(5-6):1016-25
pubmed: 21767554
Front Behav Neurosci. 2011 Sep 13;5:57
pubmed: 21949506
J Child Psychol Psychiatry. 2012 Mar;53(3):304-12
pubmed: 22066497
Psychol Addict Behav. 2012 Sep;26(3):496-506
pubmed: 22103843
Pharmacol Ther. 2013 Apr;138(1):84-102
pubmed: 23333350
Cell Tissue Res. 2013 Oct;354(1):99-106
pubmed: 23430475
Pharmacol Rev. 2013 Mar 19;65(2):849-71
pubmed: 23512546
Mol Psychiatry. 2014 May;19(5):536-43
pubmed: 24589887
Eur Neuropsychopharmacol. 2014 Aug;24(8):1337-48
pubmed: 24933531
Nat Rev Neurosci. 2014 Dec;15(12):786-801
pubmed: 25409697
J Atten Disord. 2018 Dec;22(14):1333-1343
pubmed: 25791438
Psychopharmacology (Berl). 2015 Aug;232(15):2811-25
pubmed: 25814137
Behav Brain Res. 2015 Sep 15;291:164-171
pubmed: 25979787
Stereotact Funct Neurosurg. 2015;93(4):265-70
pubmed: 26066569
Chem Phys Lipids. 2016 May;197:13-24
pubmed: 26216043
Genes Brain Behav. 2016 Jan;15(1):108-24
pubmed: 26419643
J Neurosci. 2015 Oct 14;35(41):13962-74
pubmed: 26468197
Psychopharmacology (Berl). 2016 May;233(10):1879-88
pubmed: 26558620
Transl Psychiatry. 2016 Mar 01;6:e749
pubmed: 26926885
Nat Rev Neurosci. 2016 May;17(5):293-306
pubmed: 27052382
Int J Clin Pharmacol Ther. 2016 Jul;54(7):498-501
pubmed: 27191771
BMJ. 2016 May 18;353:i2727
pubmed: 27193592
Neurosci Biobehav Rev. 2016 Nov;70:4-12
pubmed: 27235076
Recent Pat CNS Drug Discov. 2016;10(2):122-141
pubmed: 27630088
Psychopharmacology (Berl). 2017 Jul;234(13):2047-2062
pubmed: 28378204
PLoS One. 2017 May 26;12(5):e0178194
pubmed: 28552942
Eur Neuropsychopharmacol. 2017 Aug;27(8):795-808
pubmed: 28576350
J Psychopharmacol. 2017 Jun;31(6):750-756
pubmed: 28583049
Mol Psychiatry. 2018 Apr;23(4):1040-1050
pubmed: 28630452
Neuropsychopharmacology. 2018 Jan;43(1):21-33
pubmed: 28685756
Sci Rep. 2017 Aug 30;7(1):9936
pubmed: 28855580
Neuropharmacology. 2017 Nov;126:233-241
pubmed: 28890367
Eur J Clin Invest. 2018 May;48(5):e12920
pubmed: 29574698
Neuropharmacology. 2018 Aug;138:210-218
pubmed: 29842858
Psychopharmacology (Berl). 2018 Nov;235(11):3211-3221
pubmed: 30251159
Am J Psychiatry. 2019 Feb 1;176(2):98-106
pubmed: 30278790
J Abnorm Psychol. 1982 Oct;91(5):311-8
pubmed: 7142569